By Robb M. Stewart Cara Therapeutics' shares were sharply lower Monday after the biopharmaceutical company moved to discontinue its clinical program in.
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) was the recipient of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 3,420,000 shares, a growth of 15.2% from the October 31st total of 2,970,000 shares. Currently, 7.4% of the company’s shares are sold short. […]
Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript November 13, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.5. Operator: Good afternoon. My name is Latif and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Third Quarter Financial Results […]